SecBot SecBot
8-K ·Filed Aug 7, 2026

CGC

Canopy Growth Corp
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001193125-26-339131
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The broad-based revenue acceleration and margin improvement validate management's turnaround narrative, supporting the path to positive adjusted EBITDA in FY2027. Monitor the next quarter for working capital normalization (free cash flow turned negative) and continued gross margin expansion to confirm this inflection is real and not one-off.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
CGC ▲ +0.28% at T+20d
LONG call ✓ call won +0.28% · α vs SPY +0.68% · entry $0.9700 → $0.9727
Next anchor: T+60d in 6d
Latest observation: T+54 -12.16% FF3 residual α
Entry = T+0 close
Aug 7, 2026
via day close
T+1d
-1.85%
call -1.85% · α -1.82%
$0.9521
settled 3mo ago
T+5d
+5.15%
call +5.15% · α +4.76%
$1.02
settled 2mo ago
T+20d
+0.28%
call +0.28% · α +0.68%
$0.9727
settled 8w ago
T+60d
Pending
in 6d

Price Chart

Loading chart...

Executive Summary

Canopy Growth reported Q1 FY2027 net revenue of $81.2M (+13% YoY), driven by broad-based growth across all segments (Canada medical +22%, Canada adult-use +10%, international +10%, Storz & Bickel +6%). Adjusted gross margin improved to 31% from 25% a year ago, and the adjusted EBITDA loss narrowed by 59% to $3.2M. The company is progressing toward its FY2027 positive adjusted EBITDA target, though free cash outflow widened to $25.7M on working capital timing.

Key Financial Metrics

EPS
−$0.03
est −$0.03 · +6.5%
Revenue
$81.2M
est $82.7M · -1.9% · +13.0% YoY
Rating
beat
Free Cash Flow
-$25.7M
Gross Margin
27%

Key Facts

  • Consolidated net revenue of $81.2M in Q1 FY2027, up 13% year-over-year (vs $72.1M in Q1 FY2026)
  • Cannabis net revenue grew 14% to $65.1M, with Canada medical +22%, Canada adult-use +10%, international +10%
  • Storz & Bickel net revenue +6% to $16.1M, gross margin improved to 48% from 29% due to cost actions
  • Adjusted gross margin improved to 31% from 25%, with cannabis adjusted gross margin up to 26% from 24%
  • Adjusted EBITDA loss narrowed 59% to $3.2M (from $7.9M), on track for positive adjusted EBITDA in FY2027
  • Net loss narrowed 68% to $14.6M ($0.03/share) from $44.9M ($0.24/share), beating the $-0.03 EPS consensus by 6.5%
  • Free cash outflow increased to $25.7M from $11.6M, due to working capital timing; ended quarter with $336.6M cash
  • FY2027 outlook: expects net revenue growth, meaningful gross margin improvements, positive adjusted EBITDA by year-end

Financial Impact

Net revenue $81.2M, up 13% YoY; net loss $14.6M ($0.03/share) vs consensus EPS $-0.03 (6.5% beat); adjusted EBITDA loss -$3.2M

revenueearningsmarginscash flow

Risk Factors

  • Free cash flow worsened to -$25.7M on working capital timing; sustained negative FCF could pressure liquidity
  • Cannabis gross margin (GAAP) declined to 22% from 24%, though adjusted margin improved
  • Veterans Affairs Canada reimbursement reductions continue to partially offset medical cannabis growth
  • Storz & Bickel gross margin recovery reliant on tariff relief and cost actions, which may not persist

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
58% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-339131
Document: cgc-20260807.htm0001193125-26-339131
Document: 0001193125-26-339131-index-headers.html0001193125-26-339131
Document: 0001193125-26-339131-index.html0001193125-26-339131
Document: 0001193125-26-339131.txt0001193125-26-339131
8-K Data (Synthetic)0001193125-26-339131
10 reports for CGC
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for CGC — sortable, filterable
TypeNow
Oct 16, 2026
10d ago
DEFA14A
BEARISH ★ 7/10
$0.7160awaiting T+20—$0.6867 (+4.09%)
Oct 16, 2026
10d ago
8-K
BEARISH ★ 7/10
$0.7160awaiting T+20—$0.6867 (+4.09%)
Oct 6, 2026
20d ago
DEFA14A
NEUTRAL ★ 3/10
$0.8765awaiting T+20—$0.6867 (−21.65%)
Sep 25, 2026
4w ago
DEFA14A
NEUTRAL ★ 3/10
$0.9420 $0.6760▼ −28.24%▼ −26.76%$0.6867 (−27.10%)
Sep 15, 2026
5w ago
DEFA14A
NEUTRAL ★ 3/10
$0.9156 $0.7147▼ −21.94%▼ −24.00%$0.6867 (−25.00%)
Aug 17, 2026
10w ago
DEFA14A
NEUTRAL ★ 3/10
$0.9900 $0.9285▼ −6.21%▼ −5.22%$0.6867 (−30.64%)
Aug 7, 2026
11w ago
DEFA14A
NEUTRAL ★ 5/10
$0.9520 $0.9702▲ +1.91%▲ +2.83%$0.6867 (−27.87%)
Aug 7, 2026
11w ago
8-K
BULLISH ★ 6/10
$0.9700 $0.9727▲ +0.28%▲ +0.68%$0.6867 (−29.21%)
Jun 15, 2026
19w ago
8-K
BEARISH ★ 6/10
$0.9829 $0.9600▲ +2.33%▲ +1.58%$0.6867 (+30.14%)
May 15, 2026
23w ago
8-K
BEARISH ★ 6/10
$0.9820 $0.9580▲ +2.44%▲ +4.03%$0.6867 (+30.07%)
Showing 10 of 10

US Market Status

Market Open — Closes in 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026